Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.620
+0.030 (+0.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
September 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Therapeutics Update
February 06, 2022
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options
Via
NewMediaWire
Revance Therapeutics Update
January 30, 2022
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options
Via
NewMediaWire
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
July 27, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
May 23, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
May 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022
May 03, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
NASDAQ: RVNC Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Revance Therapeutics, Inc.
April 27, 2022
San Diego, CA -- (SBWIRE) -- 04/27/2022 -- An investigation on behalf of current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares over possible breaches of fiduciary duty by...
Via
SBWire
Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines
April 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
March 28, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management
March 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
February 22, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Deadline Today Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 07, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RVNC
February 05, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Filing Deadline in Class Action Lawsuit
February 05, 2022
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Revance Therapeutics Class Action Reminder
February 05, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
REVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm
February 04, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Deadline Tuesday Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 04, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC)
February 04, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Revance Therapeutics Shareholder Notice
February 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Deadline Tuesday Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 03, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Revance Therapeutics Shareholder Alert
February 02, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 02, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Revance Therapeutics Deadline Alert
February 01, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 01, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Upcoming Deadline Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 31, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.